Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.


Journal

Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150

Informations de publication

Date de publication:
10 2020
Historique:
received: 16 10 2019
revised: 01 10 2020
accepted: 01 10 2020
pubmed: 24 10 2020
medline: 1 1 2021
entrez: 23 10 2020
Statut: ppublish

Résumé

BRCA1 associated protein-1 (BAP1) germline mutations define a novel hereditary cancer syndrome, namely BAP1 tumor predisposition syndrome (BAP1-TPDS), characterized by an increased susceptibility to develop different cancer types, including mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and basal cell and squamous cell carcinoma. Currently, the role of BAP1 germline mutations in intrahepatic cholangiocarcinoma (iCCA) pathogenesis is less known. Here we report the first clinical case of a female patient who developed an iCCA when she was 47-years-old and was found to carry a novel germline mutation at a splicing site of exon 4 in BAP1 gene (NM_004656.4: c.255_255+6del). An accurate anamnesis revealed the absence of risk factors linked to iCCA development, except for a low occupational exposure to asbestos. In tumor tissue, BAP1 sequencing, multiplex ligation-dependent probe amplification and immunoistochemistry showed the loss of heterozygosity and lack of nuclear expression, suggesting that BAP1 wild-type allele and functional protein were lost in cancer cells, in line with the classical two-hit model of tumor suppressor genes. Further studies are needed to confirm whether iCCA may be included into BAP1-TPDS cancer phenotypes and whether minimal asbestos exposure may facilitate the development of this malignancy in individuals carrying BAP1 germline mutations.

Identifiants

pubmed: 33093002
pii: S2210-7762(20)30276-3
doi: 10.1016/j.cancergen.2020.10.001
pii:
doi:

Substances chimiques

BAP1 protein, human 0
Carcinogens 0
Tumor Suppressor Proteins 0
Asbestos 1332-21-4
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

57-62

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there are no competing interests.

Auteurs

G Brandi (G)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Division of Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy.

M Deserti (M)

Division of Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy.

A Palloni (A)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

D Turchetti (D)

Department of Medical and Surgical Sciences: Center for Hereditary Cancer Studies, S. Orsola-Malpighi University Hospital, Bologna, Italy.

R Zuntini (R)

Department of Medical and Surgical Sciences: Center for Hereditary Cancer Studies, S. Orsola-Malpighi University Hospital, Bologna, Italy; Medical Genetics Unit, Mother and Child Health Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

F Pedica (F)

Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

G Frega (G)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

S De Lorenzo (S)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

F Abbati (F)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

A Rizzo (A)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

M Di Marco (M)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Division of Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy.

F Massari (F)

Division of Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy.

S Tavolari (S)

Division of Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy. Electronic address: simona.tavolari@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH